Educational research on US and Indian equities, ETFs, mutual funds and crypto, with screeners and a free investing academy.
All data is for educational purposes only and should not be considered investment advice.
Equiscale is operated by Syntellia LLC, a Delaware limited liability company.
© 2026 Syntellia LLC. All rights reserved.
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey-Hailey disease; KB707 for solid tumors; KB304 for dynamic wrinkles; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
Rule-based from financial data. Not advice.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 5 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $389M | $168M | $205M | $189M | 16.8% | 33.9% | 129.7% |
| 2024 | $291M | $110M | $89M | $119M | 9.4% | 473.0% | 715.6% |
| 2023 | $51M | $-91M | $11M | $-101M | 1.4% | - | -107.8% |
| 2022 | $0M | $-117M | $-140M | $-154M | -26.8% | - | - |
| 2021 | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2025 |
|---|---|
| Total Revenue | 389.13 |
| Operating Revenue | 389.13 |
| Cost Of Revenue | 23.05 |
| Gross Profit | 366.08 |
| Operating Expense | 204.79 |
| Research And Development | 58.04 |
| Selling General And Administration | 146.74 |
| Total Expenses | 227.84 |
| Operating Income | 161.29 |
| Total Operating Income As Reported | 161.29 |
| EBITDA | 167.85 |
| Normalized EBITDA | 167.85 |
| EBIT | 161.29 |
| Interest Income | 28.18 |
| Interest Expense | - |
| Net Interest Income | 28.18 |
| Other Income Expense | - |
| Interest Income Non Operating | 28.18 |
| Interest Expense Non Operating | - |
| Net Non Operating Interest Income Expense | 28.18 |
| Pretax Income | 189.47 |
| Tax Provision | -15.36 |
| Tax Rate For Calcs | 0 |
| Tax Effect Of Unusual Items | 0 |
| Net Income Continuous Operations | 204.83 |
| Net Income From Continuing And Discontinued Operation | 204.83 |
| Net Income From Continuing Operation Net Minority Interest | 204.83 |
| Net Income | 204.83 |
| Net Income Common Stockholders | 204.83 |
| Net Income Including Noncontrolling Interests | 204.83 |
| Normalized Income | 204.83 |
| Diluted NI Availto Com Stockholders | 204.83 |
| Basic Average Shares | 28.94 |
| Diluted Average Shares | 29.95 |
| Reconciled Depreciation | 6.55 |
| Reconciled Cost Of Revenue | 23.05 |
| Total Unusual Items | 0 |
| Total Unusual Items Excluding Goodwill | 0 |
| Special Income Charges | 0 |
| Other Special Charges | - |
| General And Administrative Expense | - |
| Other Gand A | - |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Krystal Biotech, Inc.this co. | KRYS | $9.1B | 44.30↑ premium | 7.44 | 16.8% | 51.16 |
| Molina Healthcare, Inc. | MOH | $10.0B | 21.28 | 2.47 | 11.6% | - |
| Baxter International Inc. | BAX | $10.0B | -10.44 | 1.63 | -15.6% | 23.25 |
| Charles River Laboratories International, Inc. | CRL | $8.9B | - | 2.83 | -4.6% | 27.52 |
| Henry Schein, Inc. | HSIC |
| - |
| - |
| - |
| - |
| - |
| $8.7B |
| 21.84 |
| 2.68 |
| 12.3% |
| 12.42 |
| Bio-Techne Corporation | TECH | $8.3B | 113.50 | 4.34 | 3.8% | 39.69 |
| Corcept Therapeutics Incorporated | CORT | $8.0B | 80.68 | 12.41 | 15.4% | 66.11 |
| Alkermes plc | ALKS | $7.2B | 29.92 | 3.97 | 13.3% | 20.89 |
| Glaukos Corporation | GKOS | $7.1B | -38.08 | 10.89 | -28.6% | -49.02 |
| Peer Median | - | 21.84 | 3.40 | 7.7% | 23.25 | |